勁拓股份(300400.SZ):選舉王新傑為董事長
格隆匯2月28日丨勁拓股份(300400.SZ)公佈,公司原董事長徐德勇作為公司總經理、子公司深圳市思立康技術有限公司董事長,為更好地專注於半導體專用設備業務發展,近日向董事會提交書面辭職申請:自第五屆董事會第十次會議召開之日起不再擔任董事長、戰略委員會主任委員職務,辭職後繼續擔任董事、審計委員會委員、總經理職務。
經2023年2月28日召開的第五屆董事會第十次會議決議,為保證公司董事會的良好運作,公司董事會選舉王新傑為第五屆董事會董事長,任期自董事會審議通過之日起至第五屆董事會屆滿之日止。同時,董事會選舉王新傑為第五屆董事會戰略委員會主任委員,任期自董事會審議通過之日起至第五屆董事會屆滿之日止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.